Immediate Impact
59 standout
Citing Papers
Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021
2025 Standout
CAR-T therapy in solid tumors
2025 Standout
Works of Paolo Scollo being referenced
LBA33 Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial
2021
Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III–IV epithelial ovarian cancer a multicenter, randomized study
2010
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Paolo Scollo | 259 | 169 | 118 | 22 | 437 | |
| Takuhiro Hayashi | 222 | 100 | 80 | 19 | 499 | |
| Andrea P. Mann | 105 | 51 | 80 | 15 | 376 | |
| Steven M. Greenwood | 133 | 98 | 90 | 17 | 425 | |
| Rebecca Jackson | 107 | 40 | 141 | 15 | 493 | |
| G Massi | 127 | 39 | 125 | 28 | 397 | |
| Katsuji Matsuzawa | 156 | 114 | 82 | 16 | 375 | |
| David A. Figge | 110 | 46 | 117 | 13 | 388 | |
| Silaja Yitta | 33 | 61 | 45 | 17 | 439 | |
| Frederick K. Chapler | 201 | 51 | 41 | 14 | 380 | |
| Sarah Lynam | 138 | 133 | 37 | 13 | 378 |
All Works
Login with ORCID to disown or claim papers
Loading papers...